In this episode, Rick Weisseinstein of Cowen Washington Research Group speaks with Mike McCann, Founding Partner at Provisions Policy.
They discuss current events at the FDA including virtual advisory committee meetings and interesting applications with upcoming deadlines. They also speak about the state of drug manufacturing inspections amid the pandemic, a recent cluster of FDA complete response letters, Trump’s executive orders on the drug rebate rule, import policy and the international pricing index (IPI) and whether an advisory committee will be required for a COVID-19 vaccine.
Press play to listen to their conversation.
Get the Full Report
If you’re already a member of our Research portal, log in.Log In
If not, reach out to us directly for more information.